Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

Didier Meulendijks(The Netherlands Cancer Institute), Linda M. Henricks(The Netherlands Cancer Institute), Gabe S. Sonke(The Netherlands Cancer Institute), Maarten J. Deenen(Oncode Institute), Tanja K. Froehlich(University Hospital of Bern), Ursula Amstutz(University of Bern), Carlo R. Largiadèr(University Hospital of Bern), Barbara Jennings(University of East Anglia), Anthony M. Marinaki(St Thomas' Hospital), Jeremy Sanderson(St Thomas' Hospital), Zdeněk Kleibl(Charles University), Petra Kleiblová(Charles University), Matthias Schwab(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Ulrich M. Zanger(University of Tübingen), Claire Palles(Centre for Human Genetics), Ian Tomlinson(University of Oxford), Eva Groß(Technical University of Munich), André B. P. Kuilenburg(Academic Medical Center), Cornelis J.A. Punt(Academic Medical Center), Miriam Koopman(University Medical Center Utrecht), Jos H. Beijnen(The Netherlands Cancer Institute), Annemieke Cats(The Netherlands Cancer Institute), Jan H.M. Schellens(The Netherlands Cancer Institute)
The Lancet Oncology
October 25, 2015
Cited by 372Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis